BioCentury on BioBusiness,
Tools & Techniques
Nothing to sneeze at
Monday, November 16, 1998
Trials of allergy therapies frequently fall victim to strong
placebo responses in the control group. Genentech Inc. and its partners Tanox Biosystems Inc. and Novartis Pharma AG last week presented positive Phase II/III
data with their rhuMAb-E25 humanized monoclonal antibody. The next trick will
be to duplicate the results in pivotal studies.
E25 is being tested in five Phase III studies in allergic asthma
and rhinitis, and GNE expects to submit a PLA in 2000. E25 thus still faces
the same challenge in clinical trials as, for example, ImmuLogic Pharmaceutical Corp. faced with its Allervax peptide therapeutic programs for cat and ragweed
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]